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Abstract
Introduction: V2-receptor (V2R) stimulation potentially aggravates sepsis-induced vasodilation, fluid accumulation
and microvascular thrombosis. Therefore, the present study was performed to determine the effects of a first-line
therapy with the selective V2R-antagonist (Propionyl1-D-Tyr(Et)2-Val4-Abu6-Arg8,9)-Vasopressin on cardiopulmonary
hemodynamics and organ function vs. the mixed V1aR/V2R-agonist arginine vasopressin (AVP) or placebo in an
established ovine model of septic shock.
Methods: After the onset of septic shock, chronically instrumented sheep were randomly assigned to receive first-
line treatment with the selective V2R-antagonist (1 μg/kg per hour), AVP (0.05 μg/kg per hour), or normal saline
(placebo, each n = 7). In all groups, open-label norepinephrine was additionally titrated up to 1 μg/kg per minute
to maintain mean arterial pressure at 70 ± 5 mmHg, if necessary.
Results: Compared to AVP- and placebo-treated animals, the selective V2R-antagonist stabilized cardiopulmonary
hemodynamics (mean arterial and pulmonary artery pressure, cardiac index) as effectively and increased
intravascular volume as suggested by higher cardiac filling pressures. Furthermore, left ventricular stroke work index
was higher in the V2R-antagonist group than in the AVP group. Notably, metabolic (pH, base excess, lactate
concentrations), liver (transaminases, bilirubin) and renal (creatinine and blood urea nitrogen plasma levels, urinary
output, creatinine clearance) dysfunctions were attenuated by the V2R-antagonist when compared with AVP and
placebo. The onset of septic shock was associated with an increase in AVP plasma levels as compared to baseline
in all groups. Whereas AVP plasma levels remained constant in the placebo group, infusion of AVP increased AVP
plasma levels up to 149 ± 21 pg/mL. Notably, treatment with the selective V2R-antagonist led to a significant
decrease of AVP plasma levels as compared to shock time (P < 0.001) and to both other groups (P < 0.05 vs.
placebo; P < 0.001 vs. AVP). Immunohistochemical analyses of lung tissue revealed higher hemeoxygenase-1
(vs. placebo) and lower 3-nitrotyrosine concentrations (vs. AVP) in the V2R-antagonist group. In addition, the
selective V2R-antagonist slightly prolonged survival (14 ± 1 hour) when compared to AVP (11 ± 1 hour, P = 0.007)
and placebo (11 ± 1 hour, P = 0.025).
Conclusions: Selective V2R-antagonism may represent an innovative therapeutic approach to attenuate multiple
organ dysfunction in early septic shock.
Introduction
Arginine vasopressin (AVP) is recommended by the Sur-
viving Sepsis Campaign to ‘be subsequently added to nore-
pinephrine’ in volume- and catecholamine-refractory
septic shock [1]. In the randomized, controlled, multicen-
ter Vasopressin and Septic Shock Trial (VASST), however,
AVP failed to reduce overall mortality as compared with
norepinephrine among patients with septic shock [2].
AVP represents a mixed V1a/V2 receptor (V1aR/V2R)
agonist with a selectivity of 1:1 for each of these recep-
tors. Whereas particular attention has been paid to the
vasoconstriction mediated by vascular V1aRs [3,4], there
is increasing evidence that stimulation of extrarenal
(endothelial) V2Rs [5-7] may aggravate sepsis-induced
vasodilation [4,8], fluid accumulation [9], leukocyte roll-
ing [10], and microvascular thrombosis [11]. Against this
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sents a new therapeutic approach in septic shock.
We hypothesized that a first-line therapy with the
selective V2R-antagonist (propionyl1-D-Tyr(Et)2-Val4-
Abu6-Arg8,9) vasopressin [12,13] is more effective than
infusion of placebo and AVP in restoring cardiovascular
and renal functions in early ovine septic shock. Open-
label norepinephrine was additionally titrated to main-
tain mean arterial pressure (MAP) in each group if
necessary. Therefore, the present study was designed as
a prospective, randomized, controlled, laboratory experi-
ment to elucidate the effects of these treatment strate-
gies on cardiopulmonary hemodynamics, mesenteric
blood flow, global oxygen transport, acid-base balance,
organ function, AVP plasma levels, oxidative stress, and
mortality. The study hypothesis was tested in an estab-
lished ovine model of fulminant septic shock resulting
from generalized fecal peritonitis [14,15].
Materials and methods
Instrumentation and surgical procedures
After approval by the Local Animal Research Commit-
tee, 21 female sheep were anesthetized, mechanically
ventilated, and instrumented for chronic hemodynamic
monitoring using an established protocol [14,15]. Details
on the instrumentation and surgical procedures are pro-
vided in the supplemental digital content in Additional
file 1.
Experimental protocol
Following baseline (BL) measurements, autologous
feces were injected into the peritoneal cavity via an
intraperitoneal suction catheter. When septic shock
had developed (so-called ‘shock time’ [ST], defined as
MAP of less than 60 mm Hg), a second set of mea-
surements was performed. The animals were then ran-
domly assigned to receive a first-line therapy with the
selective V2R-antagonist (1 μg/kg per hour; n =7 ;
Bachem Distribution Services AG, Weil am Rhein,
Germany), AVP (0.05 μg/kg per hour, equivalent to
0.5 mU/kg per minute or 0.035 U/minute in a 70-kg
patient; n = 7; American Regent Inc., Shirley, NY,
USA), or normal saline (n =7 ;B .B r a u nM e l s u n g e n
AG, Melsungen, Germany). Open-label norepinephrine
(Arterenol; Aventis Pharma, Frankfurt, Germany) was
additionally titrated up to 1 μg/kg per minute to main-
t a i nM A Pa t7 0±5m mH gi na l lg r o u p s ,i fn e c e s s a r y .
To ensure normovolemia, continuous infusions of
balanced isotonic crystalloids (Sterofundin ISO; B.
Braun Melsungen AG, Melsungen, Germany) and 6%
hydroxyethyl starch 130/0.4 (Voluven; Fresenius Kabi,
Bad Homburg, Germany) were infused at 8 and 4 mL/
kg per hour, respectively, after ST. Additional fluids
(crystalloid/colloid ratio of 2:1) were infused if
hematocrit exceeded BL values during the 24-hour
study period [14].
Hemodynamic measurement, blood gas, laboratory, and
histological analyses
Hemodynamic measurements, arterial and mixed venous
blood gas, and laboratory analyses of variables of organ
dysfunction and AVP plasma levels were performed at
specific time points. Details on these measurements are
provided in the supplemental digital content in Addi-
tional file 1.
Immunohistochemical analyses
Following death, tissue samples were immediately stored
for immunohistochemical analyses. Pulmonary concen-
trations of hemeoxygenase-1 (StressXpress Human HO-
1 ELISA [enzyme-linked immunosorbent assay] Kit;
Stressgen Bioreagents, Ann Arbor, MI, USA) and
3-nitrotyrosine (Hycult biotechnology 3-nitrotyrosine
solid-phase ELISA; Cell Sciences, Canton, MA, USA)
were determined as described previously [16,17].
Statistical analyses
Sigma Stat 3.1 software (Systat Software, Inc., San Jose,
CA, USA) was used for statistical analyses. Analysis-of-
variance methodologies appropriate for two-factor
experiments with repeated measures across time for
each animal were used. Each variable was analyzed sepa-
rately for differences among groups and differences
across time and for group by time interaction. After
confirmation of the significance of different group
effects over time, post hoc pairwise comparisons among
groups were performed using the Student-Newman-
Keuls procedure to adjust for the elevated false-positive
rate found otherwise in multiple testing. After 10 hours,
no statistical analyses were performed, because the small
number of animals alive in the placebo and the AVP
group did not allow reliable testing anymore. Survival
times were calculated using a log-rank test. Group dif-
ferences were analyzed by pairwise multiple comparison
with the Holm-Sidak test. Differences were considered
statistically significant for P values of less than 0.05.
Results
Baseline characteristics
There were no differences among study groups in any of
the investigated variables at BL and ST. Mean body
weight (37 ± 1 kg) and time to onset of septic shock
(7 ± 1 hours) did not differ between groups.
Cardiopulmonary hemodynamics
Changes in cardiopulmonary variables are presented in
Figures 1 and 2 and Table 1. Septic shock was character-
ized by decreases in MAP, systemic vascular resistance
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(ST: P < 0.001 versus BL each). All three treatment stra-
tegies maintained MAP within the target range of 70 ±
5 mm Hg for the first 4 hours after ST (4 hours: P <0 . 0 1
versus ST each; Table 1). However, after the dose limita-
tion for norepinephrine had been reached, MAP and sys-
temic vascular resistance index fell significantly below ST
values in all groups (10 hours: P <0 . 0 5v e r s u sS Te a c h ;
Table 1). There were no statistically significant differ-
ences in cumulative norepinephrine requirements among
study groups (Figure 1a).
LVSWI increased significantly in all groups at 2 and
4h o u r s( P < 0.05 versus ST each). Notably, LVSWI was
higher in the V2R-antagonist group than in the AVP
group at 8 and 10 hours (Table 1). Left ventricular con-
tractility, expressed as a Starling-based relationship
between LVSWI and preload (pulmonary artery occlu-
sion pressure), was higher in animals treated with the
V2R-antagonist than with placebo (Figure 1b). Cardiac
index increased after ST. Heart rate was lower following
AVP infusion than in both other groups (8 hours: P =
0.027 versus V2R-antagonist; P = 0.031 versus placebo;
Table 1).
Central venous and pulmonary artery occlusion pres-
sures, as surrogate variables of cardiac filling pressures,
increased in all groups as compared with ST but were
higher in animals treated with the V2R-antagonist as com-
pared with both other groups (Figure 2a,b). Independently
Figure 1 Cumulative norepinephrine requirements (a) and left ventricular function curves (b). n = 7 each. AVP, arginine vasopressin;
LVSWI, left ventricular stroke work index; NEcum, cumulative norepinephrine dose; PAOP, pulmonary artery occlusion pressure.
Figure 2 Cardiac filling pressures. Central venous pressure (a) and pulmonary artery occlusion pressure (b).* P < 0.05 versus shock time (ST);
‡P < 0.05 versus placebo;
§P < 0.05 versus arginine vasopressin (AVP); n = 7 each. BL, baseline; CVP, central venous pressure; PAOP, pulmonary
artery occlusion pressure.
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artery pressure increased during the study period (8 and
10 hours: P < 0.05 versus ST each; Table 1).
Mesenteric blood flow
Mesenteric blood flow decreased in all groups (10 hours:
P < 0.05 versus ST each; Table 1) without any statisti-
cally significant differences among groups.
Pulmonary gas exchange and global oxygen transport
Besides a lower PaO2/FiO2 (arterial partial pressure of
oxygen/fraction of inspired oxygen) ratio in the V2R-
antagonist group compared with the placebo group at
4h o u r s( P = 0.039, Table 2), there were no statistically
significant differences between study groups in variables
of pulmonary gas exchange and global oxygen transport
(Table 2).
Capillary leakage
In all study groups, septic shock was characterized by
a marked decrease in plasma protein concentrations
(ST: P < 0.001 versus BL each) that progressed over
the study period (8 hours: P < 0.001 versus ST each;
T a b l e3 ) .A tt h es a m et i m e ,t h e r ew e r en os t a t i s t i c a ld i f -
ferences in hematocrit within or among groups (Table 2),
suggesting adequate fluid resuscitation. Cumulative posi-
tive net fluid balance was similar with all three treatment
regimes (V2R-antagonist: 19 ± 1 mL/kg per hour; AVP:
17 ± 1 mL/kg per hour; placebo: 18 ± 2 mL/kg per hour).
Metabolic changes and electrolytes
Septic shock was associated with decreases in arterial pH
and base excess (P < 0.05 versus BL each and P < 0.001
versus BL each, respectively) and increases in arterial lac-
tate concentrations (P < 0.05 versus BL each) in all groups
(Figure 3a,b and Table 2). These metabolic changes pro-
gressed during the observation period (8 hours: P < 0.001
versus ST each). However, the increase in arterial lactate
concentration was attenuated (8 and 10 hours: P <0 . 0 1
each), arterial base excess was less negative, and pH values
were higher in the selective V2R-antagonist group as
compared with the AVP and placebo groups after 8 hours
Table 1 Cardiopulmonary variables and mesenteric blood flow
Variable Group Baseline Shock time 4 hours 8 hours 10 hours
HR, beats per min Placebo 96 ± 2 103 ± 4 123 ± 7
a 115 ± 7 102 ± 5
AVP 93 ± 2 101 ± 5 112 ± 6 99 ± 5
b 100 ± 2
V2 antagonist 95 ± 4 102 ± 3 112 ± 6
a 115 ± 3
a,c 101 ± 2
CI, L/min per m
2 Placebo 5.5 ± 0.3 5.8 ± 0.5 8.6 ± 0.8
a 7.9 ± 0.5
a 5.8 ± 0.6
AVP 5.2 ± 0.3 6.5 ± 0.4 8.5 ± 0.9 6.4 ± 0.8 5.4 ± 0.8
V2 antagonist 5.3 ± 0.2 5.9 ± 0.3 9.7 ± 0.5
a 8.2 ± 0.5
a 7.1 ± 0.4
SVRI, dyne·s/cm
5 per m
2 Placebo 1,285 ± 109 758 ± 52
d 636 ± 60 463 ± 38
a 457 ± 107
a
AVP 1,427 ± 101 664 ± 47
d 596 ± 109 498 ± 84 479 ± 97
a
V2 antagonist 1,406 ± 25 714 ± 46
d 509 ± 76
a 388 ± 54
a 464 ± 75
a
MAP, mm Hg Placebo 91 ± 4 58 ± 4
d 66 ± 3
a 55 ± 3 44 ± 3
a
AVP 93 ± 2 57 ± 1
d 68 ± 2
a 56 ± 4 43 ± 1
a
V2 antagonist 96 ± 2 58 ± 1
d 68 ± 3
a 54 ± 2 51 ± 3
a
SVI, mL/m
2 Placebo 59 ± 4 58 ± 7 78 ± 3
a 68 ± 3 55 ± 7
AVP 56 ± 3 64 ± 2 80 ± 7 63 ± 7 55 ± 9
V2 antagonist 53 ± 2 57 ± 3 78 ± 7
a 71 ± 5 70 ± 3
LVSWI, g/m per m
2 Placebo 67 ± 3 41 ± 4
d 64 ± 6
a 43 ± 4 22 ± 4
a
AVP 67 ± 3 42 ± 2
d 60 ± 3
a 26 ± 2
b 21 ± 4
a
V2 antagonist 65 ± 3 37 ± 2
d 65 ± 5
a 36 ± 1
c 29 ± 2
c
MPAP, mm Hg Placebo 14 ± 1 20 ± 1
d 22 ± 1 24 ± 2
a 26 ± 2
a
AVP 15 ± 0 18 ± 1
d 22 ± 1
a 25 ± 1
a 27 ± 2
a
V2 antagonist 15 ± 1 21 ± 1
d 25 ± 2
a 27 ± 1
a 29 ± 1
a
PVRI, dyne·s/cm
5 per m
2 Placebo 106 ± 8 139 ± 22 119 ± 15 119 ± 12 144 ± 30
AVP 124 ± 9 143 ± 8 90 ± 13
a 81 ± 16
a 150 ± 29
V2 antagonist 129 ± 9 150 ± 9 121 ± 26 103 ± 8
a 123 ± 10
Qma, % of baseline Placebo 100 ± 0 109 ± 17 135 ± 27 94 ± 17 60 ± 10
a
AVP 100 ± 0 95 ± 7 118 ± 21 86 ± 16 41 ± 8
a
V2 antagonist 100 ± 0 95 ± 11 115 ± 11 75 ± 6 43 ± 8
a
aP < 0.05 versus shock time;
bP < 0.05 versus placebo;
cP < 0.05 versus arginine vasopressin (AVP);
dP < 0.05 versus baseline; each group n = 7. CI, cardiac index;
HR, heart rate; LVSWI, left ventricular stroke work index; MAP, mean arterial pressure; MPAP, mean pulmonary arterial pressure; PVRI, pulmonary vascular
resistance index; Qma, mesenteric arterial blood flow; SVI, stroke volume index; SVRI, systemic.
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chloride increased in all groups during the study period
(P < 0.05 versus ST each) without significant differences
among groups.
Laboratory variables of organ function and arginine
vasopressin plasma levels
Alanine aminotransferase and aspartate aminotransferase
activity as well as plasma concentrations of bilirubin were
reduced by the selective V2R-antagonist as compared with
placebo animals (8 hours: P < 0.05 each; Table 3). Renal
dysfunction was evidenced by a progressive increase in
blood urea nitrogen and plasma creatinine concentrations
as well as a decrease in urine output and creatinine clear-
ance in placebo animals (Figure 4 and Table 3). Infusion of
the selective V2R-antagonist was associated with an
increased creatinine clearance (4 hours: P <0 . 0 0 1 ) ,ah i g h e r
urine output (2 to 4 hours: P < 0.001 each), and lower
blood urea nitrogen levels (4 to 8 hours: P = 0.031 and P =
0.023, respectively) as compared with the placebo group.
There were no statistical differences in renal and liver func-
tion between the V2R-antagonist and the AVP group.
The onset of septic shock was associated with an increase
in AVP plasma levels as compared with BL in all groups
(P < 0.05 versus BL each; Figure 5). Whereas AVP plasma
levels remained constant in the placebo group, infusion of
AVP increased AVP plasma levels up to 149 ± 21 pg/mL.
Treatment with the selective V2R-antagonist led to a signif-
icant decrease of AVP plasma levels as compared with ST
(P < 0.001) and with both other groups (4 to 8 hours: P <
0.05 versus placebo; P < 0.001 versus AVP).
Immunohistochemical analyses
Immunohistochemical analyses of lung tissue revealed
an increase in hemeoxygenase-1 concentration in
the selective V2R-antagonist group as compared with
Table 2 Hematocrit, electrolytes, acid-base balance, and global oxygen transport
Variable Group Baseline Shock time 4 hours 8 hours 10 hours
Hct, % Placebo 30 ± 2 28 ± 2 30 ± 2 30 ± 2 27 ± 2
AVP 27 ± 2 26 ± 2 28 ± 2 27 ± 1 28 ± 2
V2 antagonist 26 ± 1 25 ± 2 27 ± 2 26 ± 2 27 ± 1
Na
+, mmol/L Placebo 141 ± 1 140 ± 1 140 ± 1 140 ± 1 140 ± 1
AVP 140 ± 1 139 ± 1 139 ± 1 139 ± 1 138 ± 1
V2 antagonist 140 ± 0 139 ± 1 140 ± 1 140 ± 1 140 ± 1
K
+, mmol/L Placebo 4.1 ± 0.1 4.3 ± 0.2 4.4 ± 0.3 5.5 ± 0.3
a 6.1 ± 0.3
a
AVP 3.8 ± 0.2 4.0 ± 0.2 4.1 ± 0.1 5.2 ± 0.3
a 5.6 ± 0.4
a
V2 antagonist 3.9 ± 0.3 4.2 ± 0.3 4.3 ± 0.2 5.1 ± 0.3 5.5 ± 0.4
a
Cl
-, mmol/L Placebo 108 ± 1 117 ± 2
b 120 ± 1 124 ± 1
a 125 ± 1
a
AVP 105 ± 1 113 ± 1
b 118 ± 1 121 ± 1
a 123 ± 1
a
V2 antagonist 108 ± 1 115 ± 2
b 118 ± 2 121 ± 2 122 ± 2
a
pHa, -log10 [H
+] Placebo 7.39 ± 0.01 7.30 ± 0.02
b 7.20 ± 0.02 7.09 ± 0.04
a 7.01 ± 0.06
a
AVP 7.42 ± 0.01 7.31 ± 0.02
b 7.22 ± 0.02 7.05 ± 0.05
a 7.04 ± 0.06
a
V2 antagonist 7.42 ± 0.02 7.33 ± 0.02
b 7.28 ± 0.01 7.22 ±0.04
c,d 7.11 ± 0.05
a
PaO2/FiO2, mm Hg Placebo 516 ± 23 458 ± 26 435 ± 43 217 ± 41
a 149 ± 32
a
AVP 488 ± 23 492 ± 55 383 ± 27
a 141 ± 25
a 160 ± 19
a
V2 antagonist 465 ± 27 412 ± 26 313 ± 20
a,c 153 ± 30
a 140 ± 26
a
SvO2, % Placebo 78 ± 3 74 ± 4 80 ± 3 74 ± 1 60 ± 4
a
AVP 78 ± 1 76 ± 2 83 ± 4 70 ± 5 72 ± 4
V2 antagonist 79 ± 2 78 ± 2 85 ± 2 78 ± 3 68 ± 4
DO2I, mL/min per m
2 Placebo 731 ± 63 719 ± 83 1,105 ± 115
a 918 ± 39 575 ± 92
AVP 641 ± 58 739 ± 65 955 ± 128 749 ± 99 620 ± 85
V2 antagonist 598 ± 36 664 ± 50 1,132 ± 139
a 936 ± 50 707 ± 64
VO2I, mL/min per m
2 Placebo 160 ± 12 179 ± 14 181 ± 19 172 ± 22 155 ± 21
AVP 163 ± 13 167 ± 8 175 ± 8 144 ± 25 123 ± 18
a
V2 antagonist 128 ± 17 153 ± 10 163 ± 17 142 ± 13 132 ± 17
O2-ER, % Placebo 23 ± 3 26 ± 3 18 ± 3 18 ± 2
a 26 ± 2
AVP 24 ± 2 25 ± 1 21 ± 6 21 ± 4 22 ± 4
V2 antagonist 20 ± 1 23 ± 1 13 ± 1
a 16 ± 2 20 ± 4
aP < 0.05 versus shock time;
bP < 0.05 versus baseline;
cP < 0.05 versus placebo;
dP < 0.05 versus arginine vasopressin; each group n = 7. AVP, arginine
vasopressin; DO2I, oxygen delivery index; Hct, hematocrit; O2-ER, oxygen extraction rate; PaO2/FiO2, ratio of arterial partial pressure of oxygen and inspiratory
oxygen fraction; pHa, arterial potentia hydrogenii; SvO2, mixed venous oxygen saturation, VO2I, oxygen consumption index.
Rehberg et al. Critical Care 2010, 14:R200
http://ccforum.com/content/14/6/R200
Page 5 of 10placebo animals (P = 0.047; Figure 6a). In addition, pul-
monary 3-nitrotyrosine concentrations were lower in
animals treated with the selective V2R-antagonist as
compared with AVP (P = 0.017; P = 0.056 versus pla-
cebo; Figure 6b).
Survival time
All animals died within 17 hours after the onset of septic
shock (Figure 7). Sheep treated with the selective V2R-
antagonist had a longer survival time (14 ± 1 hours) than
animals that received AVP (11 ± 1 hours; P =0 . 0 0 7 )o r
placebo (11 ± 1 hours; P = 0.025). There were no signifi-
cant differences in survival time between the AVP and
sole norepinephrine groups (P = 0.727).
Discussion
The major findings of the present study are that first-line
therapy with the selective V2R-antagonist (a) stabilized
cardiopulmonary hemodynamics as effectively, (b)
increased cardiac filling pressures, (c) attenuated metabolic
acidosis, (d) limited myocardial and renal dysfunction,
(e) reduced AVP plasma levels, (f) attenuated tissue injury
Table 3 Surrogate parameters of organ (dys)function
Variable Group Baseline Shock time 4 hours 8 hours
AST, U/L Placebo 71 ± 7 76 ± 6 81 ± 14 112 ± 18
a
AVP 71 ± 7 78 ± 7 80 ± 12 77 ± 8
V2 antagonist 72 ± 8 74 ± 8 58 ± 9 63 ± 10
b
ALT, U/L Placebo 7 ± 2 9 ± 1 9 ± 2 13 ± 3
AVP 8 ± 3 11 ± 1 8 ± 2 11 ± 2
V2 antagonist 8 ± 2 10 ± 3 5 ± 1 6 ± 1
b
Bilirubin, mg/dL Placebo 0.24 ± 0.02 0.24 ± 0.02 0.26 ± 0.04 0.25 ± 0.02
AVP 0.25 ± 0.02 0.23 ± 0.02 0.23 ± 0.02 0.18 ± 0.04
V2 antagonist 0.24 ± 0.02 0.23 ± 0.02 0.23 ± 0.03 0.16 ±0.03
b
Plasma protein, mg/dL Placebo 4.3 ± 0.2 1.9 ± 0.2
c 1.2 ± 0.1
a 0.7 ± 0.0
a
AVP 4.4 ± 0.2 2.1 ± 0.1
c 1.2 ± 0.1
a 0.9 ± 0.2
a
V2 antagonist 4.2 ± 0.3 1.9 ± 0.2
c 1.2 ± 0.1 0.9 ± 0.2
a
Creatinine, mg/dL Placebo 0.8 ± 0.1 0.7 ± 0.1 1.1 ± 0.1 1.5 ± 0.1
a
AVP 0.7 ± 0.1 0.7 ± 0.1 0.7 ± 0.1 1.3 ± 0.2
a
V2 antagonist 0.8 ± 0.1 0.8 ± 0.1 0.8 ± 0.1 1.1 ± 0.2
Creatinine clearance, mL/min Placebo 270 ± 82 228 ± 36 37 ± 10
a 16 ± 3
a
AVP 254 ± 29 197 ± 42 214 ± 59
b 24 ± 2
a
V2 antagonist 235 ± 43 198 ± 20 346 ± 52
b 48 ± 15
a
aP < 0.05 versus shock time;
bP < 0.05 versus placebo;
cP < 0.05 versus baseline; n = 7 each. ALT, alanine aminotransferase; AST, aspartate aminotransferase; AVP,
arginine vasopressin.
Figure 3 Arterial base excess (a) and arterial lactate concentrations (b).
†P < 0.05 versus baseline (BL); *P < 0.05 versus shock time (ST);
‡P <
0.05 versus placebo;
§P < 0.05 versus arginine vasopressin (AVP); n = 7 each. BE, base excess.
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survival in early volume-resuscitated, hyperdynamic ovine
septic shock when compared with placebo and AVP
infusion.
The relative vasopressin deficiency [18] represents the
rationale for the use of AVP in the treatment of septic
shock. However, only one third of septic shock patients
suffer from low AVP plasma levels [19]. Typically, endo-
genous AVP secretion increases in the early phase of
septic shock and decreases thereafter. Since V2Rs are
involved in several characteristic pathways of septic
shock [4-11,20], selective V2R-antagonism rather than
V2R-stimulation (for example, via AVP infusion) may be
advantageous under these circumstances.
In the present study, AVP plasma levels increased with
the onset of septic shock in all groups and remained at
this level in the placebo group during the whole study
period. The absence of a ‘relative vasopressin deficiency’
may be one reason for the ineffectiveness of AVP in
reducing norepinephrine requirements as compared
with standard treatment with norepinephrine in the pla-
cebo group. Another potential explanation is that the
AVP dose of 0.05 μg / k gp e rh o u r( e q u i v a l e n tt o
0.5 mU/kg per minute or 0.035 U/minute in a 70-kg
patient) might have been insufficient for the fulminant
injury in our model (100% mortality within 17 hours).
The latter assumption is in harmony with the observa-
tion made in VASST that AVP reduced mortality in less
severe septic shock but not in the more severe septic
shock population [2]. In this context, Torgersen and col-
leagues [21] recently reported that, in patients with sep-
sis-induced vasodilatory shock, a supplementary infusion
of 0.067 U/minute AVP was more effective in restoring
MAP and reducing norepinephrine requirements than
the recommended low dose of 0.033 U/minute.
Interestingly, infusion of the selective V2R-antagonist
reduced AVP plasma levels as compared with AVP- and
placebo-treated animals. This finding appears to be sur-
prising at first glance. In this context, however, it may
be of importance that AVP has a positive feedback on
its own release via V2R [22]. Therefore, it is most likely
that inhibition of this mechanism has accounted for the
low AVP plasma levels noticed in the V2R-antagonist
group.
Another interesting result of the present study is that
the selective V2R-antagonist was as effective as AVP in sta-
bilizing cardiopulmonary hemodynamics without increas-
ing volume and norepinephrine requirements. The
reduction in metabolic acidosis by the V2R-antagonist - as
suggested by higher pH values, less negative base excess,
and lower lactate levels as compared with both other
Figure 4 Renal function.
‡P < 0.05 versus placebo; n = 7 each. AVP, arginine vasopressin; BL, baseline; BUN, blood urea nitrogen; ST, shock time.
Figure 5 Arginine vasopressin (AVP) plasma levels.
†P <0 . 0 5
versus baseline (BL); *P < 0.05 versus shock time (ST);
‡P < 0.05
versus placebo;
§P < 0.05 versus AVP; n = 7 each. BL, baseline.
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contributed to an improved efficacy of norepinephrine by
increasing the adrenergic receptor sensitivity [24,25].
In this context, it may also be important that extrare-
nal V2R mediates vasorelaxant effects [4], thereby
decreasing MAP and vascular resistance not only in the
experimental setting [26] but also in humans [6,27].
In addition, the increased cardiac filling pressures in
animals treated with the V2R-antagonist may have
improved systemic hemodynamics. This assumption is
supported by the Starling-based relationship between
LVSWI and preload (Figure 1b). Since hematocrit
remained stable in all groups, the increased preload in
the V2R-antagonist group has most likely been caused
by a mobilization of fluid from venous capacity vessels.
Whereas both the V2R-antagonist and AVP increased
urine output and creatinine clearance as compared with
placebo animals, the V2R-antagonist additionally
reduced blood urea nitrogen versus placebo. A protec-
tive effect of V2R-antagonism on renal function is sup-
ported by Rondaij and colleagues [28], who reported
that V2R agonism caused histological renal lesions in
r a t sa n dt h a tt h e s el e s i o n sw e r ep r e v e n t e db yV 2R-
antagonism.
In addition, the reduction of oxidative stress, as sug-
gested by immunohistochemical analyses of lung tissues,
probably contributed to the attenuated organ dysfunction
in the V2R-antagonist group as compared with placebo
and AVP. Whereas 3-nitrotyrosine represents a stable
in vivo biomarker of the highly cytotoxic compound per-
oxynitrite [29], hemeoxygenase-1 has been reported to
provide cytoprotective effects [30].
Attenuation of cardiovascular, metabolic, and renal
function as well as nitrosative stress in response to first-
line V2R-antagonist infusion led to a slight prolongation
in survival time as compared with AVP and placebo
treatment. Such effects on survival time were not
observed with AVP, suggesting that its V2Ra g o n i s m
might potentially be disadvantageous.
This study has some limitations that we want to
acknowledge. In the absence of source control and anti-
biotic therapy, the present model was associated with a
high mortality (all animals died within the observation
period). As a consequence, effects of the investigated
therapeutic approaches could be analyzed only during
the acute phase of the injury. In addition, the present
study was not designed primarily for detecting differences
in mortality. For these reasons, data on survival times in
Figure 6 Pulmonary hemoxygenase-1 (a) and 3-nitrotyrosine (b) concentrations.
‡P <0 . 0 5v e r s u sp l a c e b o ;
§P < 0.05 versus arginine
vasopressin (AVP); n = 7 each. 3-NT, 3-nitrotyrosine; HO-1, hemeoxygenase-1.
Figure 7 Kaplan-Meier survival curve.
‡P < 0.05 versus placebo;
§P < 0.05 versus arginine vasopressin (AVP); n = 7 each. ST, shock
time.
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tion, conclusions on the clinical relevance of the present
findings are limited by the experimental design and the
use of previously healthy animals, whereas the majority
of patients typically suffer from comorbidities. Finally,
the risk of false-positive results in a study with numerous
outcome variables and time points has to be taken into
consideration.
Conclusions
T oo u rk n o w l e d g e ,t h i si st h ef i r s ts t u d yp r o v i d i n ge v i -
dence that, under conditions with high endogenous AVP
plasma levels, first-line treatment with the selective V2R-
antagonist supplemented with open-label norepinephrine
improves cardiovascular, metabolic, liver, and renal func-
tion and slightly prolongs survival when compared with
first-line therapy with AVP or placebo in ovine septic
shock. On the basis of the present findings, the use of
selective V2R-antagonists potentially represents a new
therapeutic approach in the early stage of septic shock.
Key messages
￿ V2-receptor stimulation aggravates sepsis-induced
vasodilation, fluid accumulation, and microvascular
thrombosis.
￿ Arginine vasopressin (AVP) infusion in septic
shock may be less effective when endogenous AVP
plasma levels are high.
￿ In ovine septic shock, selective V2-receptor-antag-
onism supplemented with open-label norepinephrine
stabilized cardiovascular hemodynamics as effectively
as combined AVP and open-label norepinephrine.
￿ Selective V2-receptor-antagonism attenuated meta-
bolic, liver, and renal dysfunction as compared with
AVP and placebo therapy in ovine septic shock.
￿ Selective V2-receptor-antagonism might represent
a useful therapeutic option in septic shock under
conditions with high endogenous AVP plasma levels.
Additional material
Additional file 1: Supplemental Digital Content. Additional
information on the methods and procedures applied in the present
study [31-33].
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